This webinar provides an overview of how liquid biopsies can be integrated into lung cancer care.

Genotyping of plasma cell-free DNA is rapidly changing the management approach for genotype-defined lung cancers. Widely available assays now have the ability to noninvasively identify driver mutations in cfDNA, monitor response to therapy, and characterize emerging resistance. However, such liquid biopsies also have clear limitations and existing assays are unlikely to replace tumor biopsies completely.

In this webinar, Geoffrey Oxnard of Dana-Farber Cancer Institute discusses an optimal approach for integrating liquid biopsies into lung cancer care, while also providing his outlook on how liquid biopsies may become a routine part of lung cancer treatment in the years ahead. 

Dr. Dimitrova discusses how the Philips IntelliSpace Genomics platform brings data from liquid biopsies (and other NGS tests) alongside disease histology and patient phenotype for a complete clinical picture for clinical decision making.